Galiximab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Galiximab
Monoclonal antibody
TypeWhole antibody
SourceChimeric (primate/human)
TargetCD80
Clinical data
ATC code
  • none
Identifiers
CAS Number
  • 357613-77-5 ☒N
ChemSpider
  • none
UNII
KEGG
 ☒NcheckY (what is this?)  (verify)

Galiximab is a monoclonal antibody designed for the treatment of B-cell lymphoma. As of September 2009, it is undergoing Phase III clinical trials.[1] The drug is a chimeric antibody from Macaca irus and Homo sapiens.[2]

References[edit]

  1. ^ "Biogen Idec: Pipeline". Archived from the original on 2008-05-17. Retrieved 2009-09-24.
  2. ^ WHO Drug Information

External links[edit]